Literature DB >> 26637299

Next Generation Sequencing in the Clinic: a Patterns of Care Study in a Retrospective Cohort of Subjects Referred to a Genetic Medicine Clinic for Suspected Lynch Syndrome.

Carlos J Gallego1,2, Matthew L Perez3, Amber Burt3, Laura M Amendola3, Brian H Shirts4, Colin C Pritchard4, Fuki M Hisama3, Robin L Bennett3, David L Veenstra5, Gail P Jarvik3.   

Abstract

Next generation sequencing (NGS) gene panels are increasingly used in medical genetics clinics for the evaluation of common inherited cancer syndromes, but the clinical efficacy of these tests, and the factors driving clinical providers to order them are unclear. We conducted a patterns-of-care study to compare patients evaluated with NGS gene panels with a reference group. We abstracted demographic, socioeconomic, and clinical information in a retrospective cohort of patients referred to a large medical genetics clinic for evaluation of inherited colorectal cancer and polyposis syndromes. Patients tested with NGS gene panels were more likely to be insured compared to the reference group (85.3 % vs. 69.2 %, p = 0.0068),less likely to have prior tumor tissue testing (29.4 % vs. 54.3 %, p = 0.0004), and less likely to have an abnormal tumor tissue test result (46.7 % vs. 74.5 %, p = 0.01). No significant differences were found between groups in age, gender, race, employment status, personal history of colorectal cancer, or proportion of patients fulfilling Lynch syndrome clinical criteria. Patients with NGS testing were less likely to have a pathogenic/likely pathogenic variant detected (13.7 % vs. 31.9 %, p = 0.002). Patients referred for NGS testing to evaluate inherited colorectal cancer/polyposis risk appear to undergo tumor tissue testing less frequently than non-NGS testing patients. Further studies are needed to assess the most effective and cost-effective approach to genomic diagnosis in this patient population.

Entities:  

Keywords:  ColoSeq; Colorectal cancer; Gene panel; Lynch syndrome; Next generation sequencing; Patterns of care

Mesh:

Year:  2015        PMID: 26637299     DOI: 10.1007/s10897-015-9902-0

Source DB:  PubMed          Journal:  J Genet Couns        ISSN: 1059-7700            Impact factor:   2.537


  10 in total

1.  The evolution of cancer risk assessment in the era of next generation sequencing.

Authors:  Heather Fecteau; Kristen J Vogel; Kristen Hanson; Shannon Morrill-Cornelius
Journal:  J Genet Couns       Date:  2014-04-24       Impact factor: 2.537

2.  Collaboration of colorado cancer genetic counselors to integrate next generation sequencing panels into clinical practice.

Authors:  K Wolfe Schneider; A Anguiano; L Axell; C Barth; K Crow; M Gilstrap; B A Hamlington; S Lesh; L Mullineaux; A Kulchak Rahm; E Strait; M Freivogel
Journal:  J Genet Couns       Date:  2014-05-01       Impact factor: 2.537

Review 3.  Human genome sequencing in health and disease.

Authors:  Claudia Gonzaga-Jauregui; James R Lupski; Richard A Gibbs
Journal:  Annu Rev Med       Date:  2012       Impact factor: 13.739

4.  Next-Generation Sequencing Panels for the Diagnosis of Colorectal Cancer and Polyposis Syndromes: A Cost-Effectiveness Analysis.

Authors:  Carlos J Gallego; Brian H Shirts; Caroline S Bennette; Greg Guzauskas; Laura M Amendola; Martha Horike-Pyne; Fuki M Hisama; Colin C Pritchard; William M Grady; Wylie Burke; Gail P Jarvik; David L Veenstra
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

5.  ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing.

Authors:  Colin C Pritchard; Christina Smith; Stephen J Salipante; Ming K Lee; Anne M Thornton; Alex S Nord; Cassandra Gulden; Sonia S Kupfer; Elizabeth M Swisher; Robin L Bennett; Akiva P Novetsky; Gail P Jarvik; Olufunmilayo I Olopade; Paul J Goodfellow; Mary-Claire King; Jonathan F Tait; Tom Walsh
Journal:  J Mol Diagn       Date:  2012-05-30       Impact factor: 5.568

6.  Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome.

Authors:  Marietta E Kovacs; Janos Papp; Zoltan Szentirmay; Szabolcs Otto; Edith Olah
Journal:  Hum Mutat       Date:  2009-02       Impact factor: 4.878

7.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.

Authors:  Asad Umar; C Richard Boland; Jonathan P Terdiman; Sapna Syngal; Albert de la Chapelle; Josef Rüschoff; Richard Fishel; Noralane M Lindor; Lawrence J Burgart; Richard Hamelin; Stanley R Hamilton; Robert A Hiatt; Jeremy Jass; Annika Lindblom; Henry T Lynch; Païvi Peltomaki; Scott D Ramsey; Miguel A Rodriguez-Bigas; Hans F A Vasen; Ernest T Hawk; J Carl Barrett; Andrew N Freedman; Sudhir Srivastava
Journal:  J Natl Cancer Inst       Date:  2004-02-18       Impact factor: 13.506

8.  Comparative effectiveness of next generation genomic sequencing for disease diagnosis: design of a randomized controlled trial in patients with colorectal cancer/polyposis syndromes.

Authors:  Carlos J Gallego; Caroline S Bennette; Patrick Heagerty; Bryan Comstock; Martha Horike-Pyne; Fuki Hisama; Laura M Amendola; Robin L Bennett; Michael O Dorschner; Peter Tarczy-Hornoch; William M Grady; S Malia Fullerton; Susan B Trinidad; Dean A Regier; Deborah A Nickerson; Wylie Burke; Donald L Patrick; Gail P Jarvik; David L Veenstra
Journal:  Contemp Clin Trials       Date:  2014-07-03       Impact factor: 2.226

Review 9.  Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies.

Authors:  Pablo Lapunzina; Rocío Ortiz López; Lara Rodríguez-Laguna; Purificación García-Miguel; Augusto Rojas Martínez; Víctor Martínez-Glez
Journal:  Genet Mol Biol       Date:  2014-03       Impact factor: 1.771

10.  Panel-based testing for inherited colorectal cancer: a descriptive study of clinical testing performed by a US laboratory.

Authors:  D Cragun; C Radford; J S Dolinsky; M Caldwell; E Chao; T Pal
Journal:  Clin Genet       Date:  2014-03-20       Impact factor: 4.438

  10 in total
  2 in total

1.  Rare loss of function variants in candidate genes and risk of colorectal cancer.

Authors:  Elisabeth A Rosenthal; Brian H Shirts; Laura M Amendola; Martha Horike-Pyne; Peggy D Robertson; Fuki M Hisama; Robin L Bennett; Michael O Dorschner; Deborah A Nickerson; Ian B Stanaway; Rami Nassir; Kathy T Vickers; Christopher Li; William M Grady; Ulrike Peters; Gail P Jarvik
Journal:  Hum Genet       Date:  2018-09-28       Impact factor: 4.132

Review 2.  Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification.

Authors:  Rick Kamps; Rita D Brandão; Bianca J van den Bosch; Aimee D C Paulussen; Sofia Xanthoulea; Marinus J Blok; Andrea Romano
Journal:  Int J Mol Sci       Date:  2017-01-31       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.